Gossamer Bio Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.377
Low
10.00
Averages
12.33
High
15.00
Current: 0.377
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by June 1, 2026.
- Clinical Trial Failure: On February 23, 2026, Gossamer reported that its PROSERA study for seralutinib in treating pulmonary arterial hypertension failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence in the company's future.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, particularly in securities and antitrust cases, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling such complex legal matters.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Gossamer Bio investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action regarding securities purchased between June 16, 2025, and February 20, 2026.
- Failed Study Results: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, causing a stock price drop of 80.3% to $0.42 per share, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that the company made materially false and misleading statements throughout the class period, failing to disclose the true performance of patients at Latin American sites, which misled investors about the company's prospects.
- Investor Rights Protection: Affected investors can contact Glancy Prongay Wolke & Rotter LLP for more information or legal support to recover losses related to their investments in Gossamer securities.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting those who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, leading to materially misleading public statements throughout the class period, which could result in substantial investor losses.
- Investor Losses: As the market became aware of Gossamer's true situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before June 1, 2026, to participate in the lawsuit and seek compensation, highlighting the urgency of legal action.
- Legal Representation Status: The class action has not yet been certified, and until certification occurs, investors are not represented by an attorney, emphasizing the vulnerable position of investors in legal proceedings and the potential impact on their rights protection.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding the viability of its PROSERA study.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Investor Losses: The concealment of critical adverse facts regarding the study design led shareholders to purchase securities at artificially inflated prices, resulting in significant losses as the stock price dropped from $2.13 to $0.42.
- Shareholder Action Advice: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, and those who choose not to participate can remain absent class members eligible for recovery.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by June 1, 2026.
- Clinical Trial Failure: On February 23, 2026, Gossamer reported that its PROSERA study for seralutinib in treating pulmonary arterial hypertension failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence in the company's future.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, particularly in securities and antitrust cases, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling such complex legal matters.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Gossamer Bio investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action regarding securities purchased between June 16, 2025, and February 20, 2026.
- Failed Study Results: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, causing a stock price drop of 80.3% to $0.42 per share, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that the company made materially false and misleading statements throughout the class period, failing to disclose the true performance of patients at Latin American sites, which misled investors about the company's prospects.
- Investor Rights Protection: Affected investors can contact Glancy Prongay Wolke & Rotter LLP for more information or legal support to recover losses related to their investments in Gossamer securities.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting those who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, leading to materially misleading public statements throughout the class period, which could result in substantial investor losses.
- Investor Losses: As the market became aware of Gossamer's true situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before June 1, 2026, to participate in the lawsuit and seek compensation, highlighting the urgency of legal action.
- Legal Representation Status: The class action has not yet been certified, and until certification occurs, investors are not represented by an attorney, emphasizing the vulnerable position of investors in legal proceedings and the potential impact on their rights protection.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding the viability of its PROSERA study.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Investor Losses: The concealment of critical adverse facts regarding the study design led shareholders to purchase securities at artificially inflated prices, resulting in significant losses as the stock price dropped from $2.13 to $0.42.
- Shareholder Action Advice: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, and those who choose not to participate can remain absent class members eligible for recovery.
See More
